Success Metrics

Clinical Success Rate
88.5%

Based on 23 completed trials

Completion Rate
88%(23/26)
Active Trials
4(10%)
Results Posted
22%(5 trials)
Terminated
3(8%)

Phase Distribution

Ph phase_4
9
23%
Ph not_applicable
7
18%
Ph phase_3
2
5%
Ph phase_1
11
28%
Ph phase_2
2
5%

Phase Distribution

11

Early Stage

2

Mid Stage

11

Late Stage

Phase Distribution31 total trials
Phase 1Safety & dosage
11(35.5%)
Phase 2Efficacy & side effects
2(6.5%)
Phase 3Large-scale testing
2(6.5%)
Phase 4Post-market surveillance
9(29.0%)
N/ANon-phased studies
7(22.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.7%

23 of 30 finished

Non-Completion Rate

23.3%

7 ended early

Currently Active

4

trials recruiting

Total Trials

39

all time

Status Distribution
Active(7)
Completed(23)
Terminated(7)
Other(2)

Detailed Status

Completed23
Withdrawn4
Not yet recruiting3
Recruiting3
Terminated3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
39
Active
4
Success Rate
88.5%
Most Advanced
Phase 4

Trials by Phase

Phase 111 (35.5%)
Phase 22 (6.5%)
Phase 32 (6.5%)
Phase 49 (29.0%)
N/A7 (22.6%)

Trials by Status

not_yet_recruiting38%
unknown25%
recruiting38%
active_not_recruiting13%
completed2359%
withdrawn410%
terminated38%

Recent Activity

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more
NCT06709521Phase 4

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

Recruiting
NCT07349797Not Applicable

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

Not Yet Recruiting
NCT03997370Phase 1

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Active Not Recruiting
NCT04649229Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Completed
NCT07174440Not Applicable

Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block

Recruiting
NCT04776486Not Applicable

Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance

Completed
NCT07391787

Low-acid Contrast Media for Preventing Post ERCP Pancreatitis

Completed
NCT02050269Phase 3

Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

Completed
NCT04113109Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Completed
NCT04582500

Virtual Colonoscopy Using Omnipaque as a Contrast Agent

Completed
NCT05442463

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Recruiting
NCT05105009Phase 1

Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function

Completed
NCT05136963Phase 1

Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance

Not Yet Recruiting
NCT06259422Not Applicable

Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate

Not Yet Recruiting
NCT02772276Phase 2

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Completed
NCT05615467Phase 1

A Study of Effect of LY3556050 on Metformin in Healthy Participants

Completed
NCT05580250Phase 1

A Study of LY3526318 in Healthy Male Japanese Participants

Withdrawn
NCT03631771Phase 4

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Withdrawn
NCT04627831Phase 2

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Withdrawn
NCT04742816Phase 4

Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
39